Latest Conference Articles

Employers may be intimidated by the idea of purchasing healthcare, but they are getting more involved in it and they are in a position to transform the market and promote value-based care, said Suzanne Delbanco, PhD, MPH, executive director of Catalyst for Payment Reform, during her keynote at The American Journal of Managed Care®’s Accountable Care Delivery Congress.

Pulling data out of an electronic health record (EHR) to be analyzed can be difficult because that’s not what these systems were typically created to do, said Pamela Tobias, MS, RHIA, CHDA, administrator of oncology services at Lehigh Valley Health Network.

Creating integrated cancer care teams is part of a paradigm shift that requires thinking of care delivery in a different way, explained Thomas Asfeldt, MBA, RN, director of Outpatient Cancer Services at Sanford Cancer Center.

Financial toxicity has been on the rise, but there has been movement toward reducing the burden through better communication and shared decision making, said Yousuf Zafar, MD, MHS, of the Duke Cancer Institute and a member of the Association of Community Cancer Centers Financial Advocacy Network Advisory Committee.

An interdisciplinary approach to patient care is very important because the treatment of gynecologic cancers can be very complex, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.

Kimberly Lenz, PharmD, clinical pharmacy manager, MassHealth/Office of Clinical Affairs, University of Massachusetts Medical School, discusses identifying patients most at risk for misusing or abusing controlled substances and how approaches to treatment differ for these patients.

M. Kristina Wharton, MPH, of the Department of Global Health Management and Policy at Tulane University School of Public Health and Tropical Medicine, recommends shifts in policies that could expand federally qualified health centers.

We have to decide if we’re prepared to not cover low-value treatments as we shift to value-based care, said Robert Navarro, PharmD, clinical professor, College of Pharmacy, University of Florida.

Both large and small causes of burnout need to be addressed, said Barbara Balik, EdD, MS, RN, co-founder of Aefina Partners and senior faculty at the Institute of Healthcare Improvement.

In a poster presentation at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York, New York, May 10 to 12, researchers reported about an adjunctive investigational drug therapy for major depressive disorder, alone and together with a selective serotonin reuptake inhibitor (SSRI), in rats resistant to SSRIs.

The field of posttraumatic stress disorder (PTSD) has grown in recent years due to veterans returning from wars in Afghanistan and Iraq, and at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York City, May 10 to 12, one of the nation’s leading experts decided to focus his presentation on the topic on memory consolidation.

Our knowledge of the human microbiome has only been developed over the past decade, according to Elaine Hsaio, PhD, assistant professor of integrative biology and physiology at the University of California, Los Angeles, at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York City, May 10 to 12. Hsaio presented about how the microbiome influences brain function, development and behavior.

Martha Gaines, MD, JD, LLM, founder and director of The Center for Patient Partnerships, clinical professor of law, University of Wisconsin Law School, explains how The Center for Patient Partnerships helps patients understand their disease, identify their treatment options, and recognize resources available to them.

Chronic pain is a serious problem in the United States and particularly so for veterans. At the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York City, May 10 to 12, Jennifer C. Naylor, PhD, presented results from a randomized control trial of 92 veterans with chronic low back pain treated with pregnenolone or placebo.

In a poster presentation at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York, New York, May 10 to 12, researchers reported on the ability of the addition of an opioid receptor antagonist to address the abuse potential of an adjunctive investigational drug therapy for major depressive disorder.

Unlike commercial plans, Medicare beneficiaries run the risk hitting the donut hole, which causes their costs to go up dramatically, said Paul Billings, senior vice president advocacy for the American Lung Association.

It is now known that early life stress may have an impact on adults later in life, and that men and women may respond to depression differently, but why that is so is not thoroughly understood. At the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York City, May 10 to 12, Eric J. Nestler, MD, PhD, gave an opening plenary called “Sex Differences in the Molecular Basis of Depression.”

There are ways to identify if a colleague is becoming burned out, but also ways people can identify burnout in themselves, explained Kathleen Blake, MD, MPH, vice president for Performance Improvement at the American Medical Association (AMA).

There are 3 legislative priorities for the Community Oncology Alliance (COA) that keep the focus on the patient and ensure better care, explained Ted Okon, executive director of COA, at the 2018 Community Oncology Conference.

The purpose of evidence-based guidelines is to reduce the level of variation, improve outcomes, and reduce costs, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

ALKS 5461 has already demonstrated efficacy versus placebo as an adjunctive major depressive disorder treatment in short-term randomized clinical trials. In a poster, researchers reported on the long-term efficacy, safety, and tolerability of the proposed therapy.

Community practices are crucial for helping to increase diversity in clinical trials, said James Hamrick, MD, MPH, Kaiser Permanente and Flatiron Health.

There are financial burdens related to cancer treatment other than the cost of medication, but patients don't always realize that when they are first diagnosed, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

Two posters presented at the American Psychiatric Association's 2018 Annual Meeting examined the factors patients with schizophrenia consider when deciding whether or not to take their medications and outcomes of a new medication to treat patients with schizophrenia and alcohol use disorder.

At the American Psychiatric Association 2018 Annual Meeting, held in New York, New York, a panel addressed the role of digital innovation in delivering mental health care.

On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, researchers presented new data on the injectable antipsychotic treatment aripiprazole lauroxil (Aristada), which is indicated for the treatment of schizophrenia.

The old ways that physicians used to coordinate care no longer work and the idea of just hiring 1 person to do it hasn’t been sufficient, said Barbara Tofani, RN, MSN, NEA-BC, administrative director of the Hunterdon Regional Cancer Center.

In a discussion during the American Psychiatric Association 2018 Annual Meeting, held in New York, New York, a panel of psychiatrists argued that private insurance is failing patients with mental health disorders, and that a single-payer system would provide better access and better care for the most seriously ill patients.

Practice reorganization can worsen clinician burnout, explained Mark Friedberg, MD, MPP, senior natural scientist and director of the Boston office at RAND Corporation, who also discussed his solutions for addressing burnout in the practice.

Since the Orphan Drug Designation program was passed in 1983, there have been over 600 orphan drug approvals, compared to less than 10 the decade before, said Stephen Jung, PharmD, BCPS, manager, drug information, MedImpact Healthcare Systems, during a session at the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting.